Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Jazz Pharmaceuticals reported a strong performance in the third quarter of 2025, achieving a record revenue surpassing $1.1 billion.</li><li>The growth was largely driven by solid sales from Xywav, Epidiolex, and the successful early launch of Modeyso.</li><li>These developments underscore the company's ability to deliver highly differentiated therapies addressing serious unmet medical needs, which is an indication of strategic execution and robust operational capabilities.</li></ul>

Jazz Pharmaceuticals reported a strong performance in the third quarter of 2025, achieving a record revenue surpassing $1.1 billion.The growth was largely driven by solid sales from Xywav, Epidiolex, and the successful early launch of Modeyso.These developments underscore the company's ability to deliver highly differentiated therapies addressing serious unmet medical needs, which is an indication of strategic execution and robust operational capabilities.

Jazz Pharmaceuticals Inside Story: How CNS & Oncology Deals Are Building a New Revenue Machine!

<ul><li>In a week dominated by biotech headlines, few announcements carried more weight than the positive Phase 3 data for Ziihera, the HER2-targeted bispecific antibody developed by Jazz Pharmaceuticals and Zymeworks.</li><li>On November 18, 2025, Jazz Pharmaceuticals reported that the HERIZON-GEA-01 trial of Ziihera (zanidatamab) in first-line treatment of HER2-positive gastroesophageal adenocarcinoma (GEA) had met its endpoints, driving strong progression-free survival and overall survival results.</li><li>This milestone marks a significant leap in treatment options for one of the world’s most aggressive and deadly cancers.</li></ul>

In a week dominated by biotech headlines, few announcements carried more weight than the positive Phase 3 data for Ziihera, the HER2-targeted bispecific antibody developed by Jazz Pharmaceuticals and Zymeworks.On November 18, 2025, Jazz Pharmaceuticals reported that the HERIZON-GEA-01 trial of Ziihera (zanidatamab) in first-line treatment of HER2-positive gastroesophageal adenocarcinoma (GEA) had met its endpoints, driving strong progression-free survival and overall survival results.This milestone marks a significant leap in treatment options for one of the world’s most aggressive and deadly cancers.

Jazz Pharmaceuticals’ Ziihera Trial Rocks the Market—A New Era in Oncology?

<ul><li>Jazz Pharmaceuticals reported a largely stable performance in the second quarter of 2025, marked by a slight increase in revenue, driven primarily by growth in its neuroscience products, particularly Xywav.</li><li>This performance reflects both positive advancements and some challenges for the company.</li><li>On the positive side, Jazz has demonstrated progress in diversifying its product portfolio and advancing its pipeline.</li></ul>

Jazz Pharmaceuticals reported a largely stable performance in the second quarter of 2025, marked by a slight increase in revenue, driven primarily by growth in its neuroscience products, particularly Xywav.This performance reflects both positive advancements and some challenges for the company.On the positive side, Jazz has demonstrated progress in diversifying its product portfolio and advancing its pipeline.

Jazz Pharmaceuticals Targets Blockbuster Growth as Epidiolex Nears $1 Billion Milestone; What Lies Ahead?

<ul><li>Jazz Pharmaceuticals reported its first-quarter 2025 financial results, reflecting both strategic advancements and challenges.</li><li>The company's total revenues reached $898 million, driven by strong performances in its neuroscience portfolio, especially with Xywav and Epidiolex, which reported year-over-year sales growth of 9% and 10%, respectively.</li><li>Xywav continues to hold its position as the leading treatment for narcolepsy and has demonstrated significant traction in treating idiopathic hypersomnia (IH), bolstered by consumer-targeted campaigns and healthcare provider education initiatives.</li></ul>

Jazz Pharmaceuticals reported its first-quarter 2025 financial results, reflecting both strategic advancements and challenges.The company's total revenues reached $898 million, driven by strong performances in its neuroscience portfolio, especially with Xywav and Epidiolex, which reported year-over-year sales growth of 9% and 10%, respectively.Xywav continues to hold its position as the leading treatment for narcolepsy and has demonstrated significant traction in treating idiopathic hypersomnia (IH), bolstered by consumer-targeted campaigns and healthcare provider education initiatives.

Jazz Pharmaceuticals: An Insight Into its Zepzelca’s Expanded Indications & Market Potential!

<ul><li>Jazz Pharmaceuticals reported record financial results for the fourth quarter and full year 2024, achieving over $4 billion in total annual revenue.</li><li>The company's growth was driven by strong execution in its sleep, epilepsy, and oncology portfolios.</li><li>Fourth quarter revenues nearly reached $1.1 billion, marking the highest figure in the company's history.</li></ul>

Jazz Pharmaceuticals reported record financial results for the fourth quarter and full year 2024, achieving over $4 billion in total annual revenue.The company's growth was driven by strong execution in its sleep, epilepsy, and oncology portfolios.Fourth quarter revenues nearly reached $1.1 billion, marking the highest figure in the company's history.

Jazz Pharmaceuticals: Is Its Zepzelca Market Expansion & Indications to Reinforce The Oncology Portfolio?

Ireland

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Jazz Pharmaceuticals (JAZZ US)

Jazz Pharmaceuticals Inside Story: How CNS & Oncology Deals Are Building a New Revenue Machine!

Jazz Pharmaceuticals reported a strong performance in the third quarter of 2025, achieving a record revenue surpassing $1.1 billion. The growth...

Baptista Research

Jazz Pharmaceuticals’ Ziihera Trial Rocks the Market—A New Era in Oncology?

In a week dominated by biotech headlines, few announcements carried more weight than the positive Phase 3 data for Ziihera, the HER2-targeted...

Baptista Research

Jazz Pharmaceuticals Targets Blockbuster Growth as Epidiolex Nears $1 Billion Milestone; What Lies Ahead?

Jazz Pharmaceuticals reported a largely stable performance in the second quarter of 2025, marked by a slight increase in revenue, driven primarily...

Baptista Research

Jazz Pharmaceuticals: An Insight Into its Zepzelca’s Expanded Indications & Market Potential!

Jazz Pharmaceuticals reported its first-quarter 2025 financial results, reflecting both strategic advancements and challenges. The company's total...

Baptista Research

Jazz Pharmaceuticals: Is Its Zepzelca Market Expansion & Indications to Reinforce The Oncology Portfolio?

Jazz Pharmaceuticals reported record financial results for the fourth quarter and full year 2024, achieving over $4 billion in total annual...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)